The lack of knowledge about the prognostic and therapeutic impact of HER2/neu expression in ovarian cancer may be partly explained by its lower prevalence in the general population resulting in slower patient recruitment and underpowered studies. This evidence concerns the gene ERBB2 and ovarian cancer.